<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Overview of gastrointestinal toxicity of radiation therapy</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Overview of gastrointestinal toxicity of radiation therapy</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Overview of gastrointestinal toxicity of radiation therapy</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Brian G Czito, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jeffrey J Meyer, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Christopher G Willett, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Reed E Drews, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Shilpa Grover, MD, MPH, AGAF</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Dec 04, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Gastrointestinal toxicity can occur following irradiation of thoracic, abdominal, or pelvic malignancies if gastrointestinal structures are located within the radiation therapy (RT) field. These toxicities can limit the maximum tolerated dose of RT and chemotherapy and thus may limit the efficacy of treatment. The incidence and severity of radiation-induced gastrointestinal morbidity depends on both total dose and fraction size, treatment volumes and techniques, the presence or absence of other treatment modalities such as systemic therapy and surgery, and underlying patient comorbidities. The functional arrangement of organs in the gastrointestinal tract can also influence the clinical presentation. The functional arrangement of organs in the GI tract can be categorized as either serial or parallel. Organs arranged in series consist of segments that are reliant on the functionality of the preceding segment such that the loss of any individual segment will make the organ dysfunctional or even nonfunctional downstream, and possibly upstream, from the insult. Much of the luminal gastrointestinal tract has this type of organization. Organs with parallel architecture, on the other hand, have some functional redundancy built in such that the loss of segments up to a point may not manifest clinically. The liver has this type of arrangement. Organs in series are subject to maximum radiation dose constraints given an ablative dose to a small area can manifest as dysfunction of the entire organ. Organs with a parallel functional architecture are subject to constraints that allow for the protection of an adequate relative volume of functional tissue. </p><p>This topic will review the adverse effects of RT on the gastrointestinal tract. A more detailed discussion of the indications for RT for specific cancer sites and stages can be found in topic reviews for each cancer site. (See  <a class="medical medical_review" href="/z/d/html/89528.html" rel="external">"Radiation therapy techniques in cancer treatment"</a>.)</p><p class="headingAnchor" id="H102084414"><span class="h1">TIMING OF TOXICITY</span><span class="headingEndMark"> — </span>RT can be associated with side effects that can occur at any time during treatment or even years later. For purposes of this topic review, we will adopt the following definitions of these toxicities:</p><p class="bulletIndent1"><span class="glyph">●</span>Acute toxicities refer to those with onset during or shortly after the course of treatment.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Late toxicities are those occurring after three months after completion of RT. These often reflect the spectrum of radiation tissue changes that can be lasting and irreversible. </p><p></p><p class="headingAnchor" id="H2"><span class="h1">ESOPHAGITIS</span></p><p class="headingAnchor" id="H3182765280"><span class="h2">Pathogenesis and risk factors</span><span class="headingEndMark"> — </span>Normal esophageal mucosa undergoes continuous cell turnover and renewal. Acute radiation esophagitis is primarily due to effects on the basal epithelial layer. This causes a thinning of the mucosa, which can progress to denudation. The late effects of radiation therapy (RT) are believed to be due to inflammation and scar formation within the esophageal musculature.</p><p>The radiation dose to the esophagus, technique used for RT administration, the use of concurrent chemotherapy, and the presence of underlying esophageal disease (eg, erosion, gastroesophageal reflux disease [GERD]) influence the likelihood of esophageal complications [<a href="#rid1">1-4</a>]. </p><p>These results are illustrated by the following examples (see  <a class="medical medical_review" href="/z/d/html/2478.html" rel="external">"Radiation therapy, chemoradiotherapy, neoadjuvant approaches, and postoperative adjuvant therapy for localized cancers of the esophagus"</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>In a retrospective study of 91 patients who were treated with high-dose conformal RT, the percentage of esophageal volume and surface area treated to &gt;50 Gy predicted late esophageal toxicity [<a href="#rid5">5</a>]. Patients who had preexisting GERD or esophageal erosion secondary to tumor were at increased risk. Hyperfractionation was associated with increased incidence of acute toxicity. Similarly, the addition of concurrent chemotherapy to RT appears to increase the incidence of both acute and chronic esophageal toxicity. </p><p>The Radiation Therapy Oncology Group (RTOG) 0617 trial compared total doses of 60 Gy versus 74 Gy in the treatment of locally advanced non-small cell lung cancer. A threefold increase in &gt;Grade 3 esophagitis was also noted in the higher dose arm [<a href="#rid6">6</a>]. In the RTOG 85-01, a randomized trial comparing definitive radiotherapy to 64 Gy and conformal radiation therapy to 50 Gy, nearly 20 percent of patients in each arm experienced severe late esophageal toxicity [<a href="#rid7">7</a>]. However, analyses of patients treated with modern planning techniques have found significant reduction in the long-term esophageal sequelae [<a href="#rid8">8</a>]. </p><p class="bulletIndent1"><span class="glyph">●</span>A study of 207 patients who received conformal daily RT with or without concurrent chemotherapy found that a maximal esophageal "point" dose of 69 Gy with RT alone and 58 Gy with concurrent chemotherapy predicted significant esophageal toxicity. Severe toxicity was more common in those receiving concurrent chemotherapy (26 versus 1 percent with RT alone) [<a href="#rid9">9</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Multiple trials conducted by the Radiation Therapy Oncology Group found that the incidence of severe esophageal toxicity was significantly increased when chemotherapy was given concurrently with hyperfractionated RT, compared with sequential use of chemotherapy followed by RT or with sequential and concurrent chemotherapy with once-daily RT (34 versus 1 and 6 percent, respectively) [<a href="#rid10">10</a>].</p><p></p><p class="headingAnchor" id="H630600759"><span class="h2">Clinical manifestations</span></p><p class="headingAnchor" id="H1804891974"><span class="h3">Acute</span><span class="headingEndMark"> — </span>Symptoms of acute radiation esophagitis include dysphagia, odynophagia, and substernal discomfort. Symptoms usually occur within two to three weeks of initiation of RT. Patients may describe a sudden, sharp, severe chest pain radiating to the back. Acute toxicity rarely causes esophageal perforation or bleeding [<a href="#rid11">11</a>]. Complete epithelial recovery from radiation effects may take 3 to 24 months [<a href="#rid12">12</a>]. </p><p class="headingAnchor" id="H2497529480"><span class="h3">Late</span><span class="headingEndMark"> — </span>Late effects may be seen within three months of completion of RT, with a median time to onset of six months [<a href="#rid13">13,14</a>]. Patients often present with dysphagia secondary to stricture or altered motility caused by fibrosis/muscular damage or nerve injury or odynophagia due to chronic ulceration. Rarely patients may develop a tracheoesophageal fistula and present with dyspnea secondary to aspiration pneumonia.</p><p class="headingAnchor" id="H860087040"><span class="h2">Diagnosis</span><span class="headingEndMark"> — </span>The diagnosis of radiation esophagitis is suspected in patients with dysphagia or odynophagia and a history of RT. Upper endoscopy and biopsy serve to establish the diagnosis and rule out other etiologies. (See <a class="local">'Differential diagnosis'</a> below.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Upper endoscopy</strong> – Patients with acute radiation esophagitis may have mucositis and ulceration [<a href="#rid11">11</a>]. After completion of treatment, basal proliferation and regeneration occur, usually within three weeks [<a href="#rid15">15</a>]. In patients with late radiation esophagitis, esophageal strictures or ulcerations may be seen. Histologic findings include epithelial thickening, chronic inflammation, and submucosal or muscularis fibrosis.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Imaging</strong> – We consider performing a <a class="drug drug_general" data-topicid="9180" href="/z/d/drug information/9180.html" rel="external">barium</a> swallow in patients with a suspected esophageal stricture. Barium swallow can establish the location, length, and number of strictures, determine the diameter of the esophageal lumen, and look for associated pathology such as esophageal diverticula or a hiatal hernia. This information is used to select the dilating technique, to determine the number of sessions that will be required to relieve symptoms, and to counsel the patient about the expected risks of dilation. Barium swallow may demonstrate disrupted peristalsis, with repetitive, nonperistaltic waves above and below the irradiated segment of the esophagus. Evidence of abnormal peristalsis may be observed as early as one to three months after completion of treatment. </p><p></p><p class="headingAnchor" id="H340138448"><span class="h2">Differential diagnosis</span><span class="headingEndMark"> — </span>The differential diagnosis of radiation esophagitis includes infectious esophagitis in patients with acute radiation esophagitis and malignancy in patients with late onset of dysphagia. Other causes of dysphagia are listed in the table  (<a class="graphic graphic_table graphicRef80528" href="/z/d/graphic/80528.html" rel="external">table 1</a>). (See  <a class="medical medical_review" href="/z/d/html/2427.html" rel="external">"Esophageal candidiasis in adults", section on 'Epidemiology'</a>.)</p><p></p><p class="headingAnchor" id="H5"><span class="h2">Management</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Acute esophagitis</strong> – Acute esophagitis is managed symptomatically. Although interruption of RT is occasionally necessary because of severe symptoms, this approach may compromise treatment efficacy and should be avoided whenever possible.</p><p></p><p class="bulletIndent1">Management measures in patients with dysphagia or odynophagia due to esophagitis or esophageal ulceration include:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Topical anesthetics (viscous lidocaine-based formulations), analgesics (antiinflammatory agents, <a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">acetaminophen</a>, narcotics), coating agents (<a class="drug drug_general" data-topicid="9953" href="/z/d/drug information/9953.html" rel="external">sucralfate</a>), antisecretory therapy (proton pump inhibitors, H2 receptor blockers), and treatment of superimposed infection (candidiasis).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Dietary modification (bland, pureed, or soft foods, soups) to help a patient maintain adequate caloric and liquid intake [<a href="#rid16">16</a>]. Eating more frequent, smaller meals and avoiding foods that are very hot or very cold may also be useful. Avoidance of smoking, alcohol, coffee, spicy or acidic foods or liquids, chips, crackers, and fatty and indigestible foods can be helpful. A study of dietary modifications and pharmacologic prophylaxis for radiation-induced esophagitis reported decreased toxicity and fewer treatment interruptions. It was recommended to drink between meals and to eat six smaller meals per day, consisting of semisolid food, soup, high-calorie supplements, purees, puddings, milk, and soft breads [<a href="#rid16">16</a>]. In addition, ingestion of hot or cold foods should be avoided if possible; instead, foods and liquids should be at room temperature. In severe cases, feeding tube placement may be required.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Esophageal strictures</strong> – Esophageal strictures are generally managed with endoscopic dilation. This approach usually results in symptomatic improvement, although multiple dilations may be required. Extended use of proton pump inhibitors following dilation may decrease the risk of stricture recurrence. Tube feedings are only rarely required for patients with significant weight loss or those able to ingest only liquids. (See  <a class="medical medical_review" href="/z/d/html/2270.html" rel="external">"Endoscopic interventions for nonmalignant esophageal strictures in adults"</a>.)</p><p></p><p class="bulletIndent1">Dilation of a stricture can cause esophageal rupture, and this approach should be performed carefully. Surgical intervention may be required for patients who develop a perforation or fistula. (See  <a class="medical medical_review" href="/z/d/html/2275.html" rel="external">"Complications of endoscopic esophageal stricture dilation"</a>.)</p><p></p><p class="headingAnchor" id="H9"><span class="h1">GASTRITIS</span></p><p class="headingAnchor" id="H2941323550"><span class="h2">Pathogenesis and risk factors</span><span class="headingEndMark"> — </span>Irradiation of the stomach as a consequence of treatment of a range of tumors can cause early and/or delayed toxicity. Low doses of radiation therapy (RT) can cause a decrease in gastric acid production, coagulation necrosis of chief and parietal cells, mucosal thinning, edema, and chronic inflammatory infiltration [<a href="#rid14">14,17</a>]. Acute ulceration results from desquamation and erosion of the damaged mucosa. </p><p>Risk factors for gastritis include the radiation dose and use of concurrent chemotherapy.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Radiation dose</strong> – The TD5/5 (the dose at which 5 percent of patients develop complications at five years) when the entire stomach is irradiated is estimated to be 50 Gy. The risk of late effects appears to be increased when larger dose fractions are used or when the patient has had prior abdominal surgery [<a href="#rid18">18-21</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Concurrent chemotherapy</strong> – Concurrent chemotherapy decreases the tolerance of the gastric mucosa to radiation. Acute gastric side effects are increased when RT is given with taxanes, <a class="drug drug_general" data-topicid="8487" href="/z/d/drug information/8487.html" rel="external">gemcitabine</a>, and epidermal growth factor or tyrosine kinase inhibitors. Although <a class="drug drug_general" data-topicid="8464" href="/z/d/drug information/8464.html" rel="external">fluorouracil</a> is a radiation sensitizer, it has been given with RT at doses of 45 to 50 Gy without substantial increases in toxicity. </p><p></p><p class="headingAnchor" id="H10"><span class="h2">Clinical manifestations</span></p><p class="headingAnchor" id="H11"><span class="h3">Acute</span><span class="headingEndMark"> — </span>Nausea and vomiting may occur within 24 hours after the start of treatment. Approximately one-half of patients receiving upper abdominal irradiation will experience emesis within two to three weeks of the start of treatment [<a href="#rid22">22</a>]. Other early effects of gastric irradiation include nausea, vomiting, dyspepsia, anorexia, abdominal pain, and malaise. Symptoms generally resolve within one to two weeks following completion of RT. These symptoms may be accompanied by development of acute ulceration, occurring shortly after completion of RT [<a href="#rid23">23</a>]. </p><p class="headingAnchor" id="H12"><span class="h3">Late</span><span class="headingEndMark"> — </span>Patients may present with abdominal pain. These symptoms may be due to nonulcer dyspepsia, late gastric ulceration (which usually occurs approximately five months after irradiation), or antral stenosis (which can occur approximately 1 to 12 months after irradiation).  </p><p class="headingAnchor" id="H3267715313"><span class="h2">Diagnosis</span><span class="headingEndMark"> — </span>A presumptive diagnosis of radiation gastritis is often made in patients with mild symptoms of nausea, vomiting, and abdominal pain during or shortly after RT. However, in patients with severe or late (&gt;3 months after RT) symptoms, we recommend upper endoscopy to establish the diagnosis and rule out other etiologies. Endoscopic findings of radiation gastritis include mucosal erosions, ulceration, mucosal atrophy, and antral stenosis. The diagnosis and evaluation of nausea, vomiting, and abdominal pain are discussed in detail, separately. (See  <a class="medical medical_review" href="/z/d/html/2537.html" rel="external">"Approach to the adult with nausea and vomiting"</a> and  <a class="medical medical_review" href="/z/d/html/6862.html" rel="external">"Evaluation of the adult with abdominal pain"</a>.)</p><p class="headingAnchor" id="H2962372396"><span class="h2">Differential diagnosis</span><span class="headingEndMark"> — </span>The differential diagnosis in patients with acute onset of nausea and vomiting includes acute gastroenteritis. The differential diagnosis of abdominal pain includes other causes of dyspepsia and includes celiac disease, gastric malignancy, chronic pancreatitis, biliary disease, and drug-induced dyspepsia. The differential diagnosis and diagnostic evaluation of nausea, vomiting, and abdominal pain are discussed in detail, separately. (See  <a class="medical medical_review" href="/z/d/html/2537.html" rel="external">"Approach to the adult with nausea and vomiting"</a> and  <a class="medical medical_review" href="/z/d/html/6862.html" rel="external">"Evaluation of the adult with abdominal pain"</a>.)</p><p class="headingAnchor" id="H1134990312"><span class="h2">Management</span><span class="headingEndMark"> — </span>Nausea and vomiting are generally managed with antiemetics. The prevention and management of radiation-induced nausea and vomiting are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/7052.html" rel="external">"Radiotherapy-induced nausea and vomiting: Prophylaxis and treatment"</a>.)</p><p>Patients with abdominal pain and dyspepsia should be treated with antisecretory medications, including a proton pump inhibitor and/or H2 blockers, as well as <a class="drug drug_general" data-topicid="9953" href="/z/d/drug information/9953.html" rel="external">sucralfate</a>. These may be helpful on a long-term basis to avoid late ulceration. Patients with severe pain may require narcotic and non-narcotic analgesics as needed. In rare instances, endoscopic therapeutic approaches or even surgery may be required to treat severe bleeding, refractory ulceration, gastric outlet obstruction, fistula formation, or perforation. (See  <a class="medical medical_review" href="/z/d/html/24.html" rel="external">"Overview of complications of peptic ulcer disease"</a>.)</p><p class="headingAnchor" id="H14"><span class="h1">ENTERITIS</span><span class="headingEndMark"> — </span>Radiation therapy (RT) can cause an acute injury to the small and large intestines that develops during or shortly after treatment of a variety of malignancies. The initial toxicity generally resolves within a matter of weeks, but chronic changes can develop months or years after therapy. </p><p class="headingAnchor" id="H15"><span class="h2">Pathogenesis</span><span class="headingEndMark"> — </span>The gastrointestinal epithelium has a high proliferative rate, making it susceptible to injury from both radiation and chemotherapy. The primary effect of radiation is on mucosal stem cells within the crypts of Lieberkühn. Stem cell damage, either acutely as a direct consequence of radiation or subsequently as a result of microvascular damage, leads to a decrease in cellular reserves for the intestinal villi. This results in mucosal denudation with associated intestinal inflammation, edema, shortened villi, and decreased absorptive area.</p><p>The initial histologic evidence of damage is seen within hours of irradiation. This is followed by an infiltration of leukocytes with crypt abscess formation within two to four weeks; ulceration may also occur. Subsequent changes include a progressive occlusive vasculitis with foam cell invasion of the intima and hyaline thickening of the arteriolar walls, as well as collagen deposition and fibrosis, often in the submucosal layer [<a href="#rid24">24</a>].</p><p>The small bowel becomes thickened [<a href="#rid25">25</a>]. The vessel walls of small arterioles are obliterated, causing ischemia. Lymphatic damage results in constriction of the lymphatic channels, which contributes to mucosal edema and inflammation [<a href="#rid26">26</a>]. The mucosa is atrophied, with atypical hyperplastic glands and intestinal wall fibrosis [<a href="#rid12">12</a>]. Telangiectasias may be present and can cause bleeding. (See  <a class="medical medical_review" href="/z/d/html/2576.html" rel="external">"Argon plasma coagulation in the management of gastrointestinal hemorrhage"</a>.)</p><p>Mucosal ulcerations can lead to perforation, fistulas, or abscess formation. As the ulcers heal, there can be fibrosis with narrowing of the intestinal lumen and stricture formation or even obstruction. Stasis can lead to small intestinal bacterial overgrowth. Even if the intestine appears normal, patients are at risk of spontaneous perforation [<a href="#rid27">27</a>].</p><p>These chronic changes can impair absorption of fats, carbohydrates, protein, bile salts, and vitamin B12, leading to loss of water, electrolytes, and protein in the small intestine [<a href="#rid28">28,29</a>]. Lactose degradation may be impaired, which can lead to increased bacterial fermentation and associated flatulence, abdominal distention, and diarrhea, possibly accompanied by bacterial overgrowth [<a href="#rid30">30</a>]. There is also evidence of altered gut motility acutely following RT. Bile salt resorption may be impaired, causing increased amounts of conjugated bile salts to enter the colon. These bile salts are then deconjugated by bacteria, resulting in intraluminal water retention with resultant diarrhea. The large intestine is generally believed to be less radiosensitive than the small intestine. When radiation injury does involve the colon, patients can develop a pancolitis that mimics inflammatory bowel disease (IBD). </p><p class="headingAnchor" id="H2740575947"><span class="h2">Risk factors</span><span class="headingEndMark"> — </span>A number of factors can affect the risk of developing radiation enteritis, including the dose of radiation to the intestines and the use of concomitant chemotherapy. There is some evidence that patients who develop acute intestinal toxicity are at increased risk for chronic effects [<a href="#rid31">31</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dose and schedule of RT</strong> – The total RT dose, fraction size, treatment duration, and volume of intestine within the RT field all influence the likelihood of enterotoxicity. Mitigating the risk and severity of radiation enteritis and chronic small bowel injury is commonly the radiation dose-limiting factor in the radiotherapeutic management of most abdominal and pelvic malignancies, emphasizing the importance of careful radiation planning. The radiation dose at which 5 percent of patients will develop complications at five years (TD5/5) for limited volumes of small bowel is estimated to be 50 Gy. Significant intestinal toxicity is rare when treatment is limited to 45 to 50 Gy in 1.8 to 2.0 Gy daily fractions [<a href="#rid32">32</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Chemotherapy</strong> – Combining chemotherapy with RT increases the risk of radiation enteritis. Several studies in patients treated with <a class="drug drug_general" data-topicid="8464" href="/z/d/drug information/8464.html" rel="external">fluorouracil</a> (FU)-based chemoradiotherapy for rectal cancer have found a strong correlation between acute toxicity and the amount of small bowel irradiated at each dose level analyzed [<a href="#rid33">33-35</a>]. Limiting the volume of small bowel receiving &gt;15 Gy in patients receiving concomitant chemotherapy may decrease the occurrence of severe diarrhea and improve treatment tolerance [<a href="#rid35">35</a>]. Data from phase I and II studies suggest that integration of agents such as <a class="drug drug_general" data-topicid="10180" href="/z/d/drug information/10180.html" rel="external">oxaliplatin</a>, <a class="drug drug_general" data-topicid="8573" href="/z/d/drug information/8573.html" rel="external">irinotecan</a>, and vascular endothelial growth factor (VEGF) receptor and epidermal growth factor receptor (EGFR) inhibitors with RT may significantly increase the frequency of severe gastrointestinal toxicity as compared with 5-FU-based regimens [<a href="#rid36">36-38</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other risk factors</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Limited bowel mobility</strong> – Factors that limit bowel mobility within the abdomen increase the amount of radiation delivered to a specific segment of the intestines. This increased focal irradiation can cause increased toxicity. Bowel mobility may be decreased in the following groups of patients:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Females, older patients, and thin patients may have larger volumes of small bowel in the pelvic cul-de-sac [<a href="#rid39">39</a>]</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Prior abdominal or pelvic surgery, which can cause adhesions that limit intestinal mobility [<a href="#rid40">40-42</a>]</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Previous pelvic inflammatory disease or endometriosis that may result in scarring and decreased bowel mobility [<a href="#rid43">43,44</a>]</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Vascular disease</strong> – Patients with preexisting vascular disease due to smoking, diabetes, hypertension, or atherosclerosis appear to be at increased risk for radiation enteritis [<a href="#rid45">45</a>]. The pretreatment abnormalities are exacerbated by the pathologic changes of chronic radiation injury, which include vasculitis obliterans and ischemia. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Collagen vascular disease </strong>– Patients with collagen vascular disease (eg, rheumatoid arthritis, systemic lupus erythematosus, polymyositis) may have a lower gastrointestinal tolerance to radiation and an increased risk of acute and chronic radiation-induced injury [<a href="#rid46">46-49</a>]. The late effects induced by RT can be additive to these preexisting changes that include transmural fibrosis, collagen deposition, and inflammatory infiltration of the mucosa. Patients whose comorbid disease is quiescent or well controlled appear to fare better than patients with active disease. (See <a class="local">'Pathogenesis'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Inflammatory bowel disease</strong> – Patients with IBD may be at an increased risk of acute and late bowel complications, particularly if active and/or poorly controlled, although the data appear to be conflicting, especially when trying to tease out the effects related to RT from those that might be related to the natural history of IBD [<a href="#rid47">47,48,50</a>]. </p><p></p><p class="headingAnchor" id="H16"><span class="h2">Clinical manifestations</span></p><p class="headingAnchor" id="H17"><span class="h3">Acute</span><span class="headingEndMark"> — </span>Symptoms of acute radiation enteritis include diarrhea, abdominal cramping and pain, nausea and vomiting, anorexia, and malaise. Radiation-induced diarrhea often appears during the third week of treatment, with reports of frequency ranging from 20 to 70 percent [<a href="#rid51">51</a>]. Diarrhea may occur after doses of 18 to 22 Gy delivered using conventional fractionation and will occur in most patients who receive doses of 40 Gy. The symptoms subside as the acute pathologic effects resolve, and typically disappear two to six weeks after the completion of RT [<a href="#rid52">52</a>]. Patients who develop acute small intestinal toxicity may be at higher risk for late effects.</p><p class="headingAnchor" id="H18"><span class="h3">Late</span><span class="headingEndMark"> — </span>Late radiation effects typically manifest 8 to 12 months after RT, although toxicity may not appear until years later in some cases [<a href="#rid14">14,53</a>]. In some cases, the clinical manifestations of chronic radiation enteritis worsen over time.</p><p>Late effects include dysmotility, stricture formation, malabsorption, and diarrhea. Patients may have bloating, excessive gas, and borborygmi due to small intestinal bacterial overgrowth. Other symptoms include bleeding or abdominal pain due to ulceration, and fever secondary to abscess formation. Patients with severe disease may develop intermittent, partial, or complete small bowel obstruction due to strictures [<a href="#rid54">54</a>]. (See  <a class="medical medical_review" href="/z/d/html/8037.html" rel="external">"Etiologies, clinical manifestations, and diagnosis of mechanical small bowel obstruction in adults"</a>.)</p><p>Laboratory findings include vitamin B12 deficiency due to small intestinal bacterial overgrowth, and hypoalbuminemia and anemia due to malnutrition or bleeding. (See  <a class="medical medical_review" href="/z/d/html/4776.html" rel="external">"Small intestinal bacterial overgrowth: Clinical manifestations and diagnosis", section on 'Laboratory findings'</a>.)</p><p class="headingAnchor" id="H2205207169"><span class="h2">Diagnosis</span><span class="headingEndMark"> — </span>The diagnosis of acute radiation enteritis is suspected in patients with diarrhea and abdominal pain during the course of radiation treatment. While the diagnosis can be made based on clinical history, in patients with diarrhea we sometimes perform stool cultures to rule out other causes of infectious diarrhea. CT imaging may reveal thickened loops of bowel correlating with the radiation portal. The diagnosis of chronic radiation enteritis is discussed in detail, separately. (See  <a class="medical medical_review" href="/z/d/html/4057.html" rel="external">"Diagnosis and management of chronic radiation enteritis", section on 'Diagnosis'</a>.)</p><p class="headingAnchor" id="H3365086085"><span class="h2">Differential diagnosis</span><span class="headingEndMark"> — </span>The differential diagnosis of acute radiation enteritis includes infectious gastroenteritis. The differential diagnosis of chronic radiation enteritis is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/2717.html" rel="external">"Approach to the adult with acute diarrhea in resource-abundant settings", section on 'Etiology'</a> and  <a class="medical medical_review" href="/z/d/html/4057.html" rel="external">"Diagnosis and management of chronic radiation enteritis", section on 'Differential diagnosis'</a>.)</p><p class="headingAnchor" id="H3982475507"><span class="h2">Management</span><span class="headingEndMark"> — </span>The management of chronic radiation enteritis is discussed in detail, separately. (See  <a class="medical medical_review" href="/z/d/html/4057.html" rel="external">"Diagnosis and management of chronic radiation enteritis", section on 'Management'</a>.)</p><p class="headingAnchor" id="H24"><span class="h1">PROCTITIS</span><span class="headingEndMark"> — </span>Radiation proctitis is usually encountered following treatment of cancers of the anus, rectum, cervix, uterus, prostate, urinary bladder, and testes. Radiation proctitis is discussed in more detail, separately. (See  <a class="medical medical_review" href="/z/d/html/7058.html" rel="external">"Radiation proctitis: Clinical manifestations, diagnosis, and management"</a>.)</p><p class="headingAnchor" id="H25"><span class="h1">ANAL TOXICITY</span></p><p class="headingAnchor" id="H26"><span class="h2">Pathogenesis and risk factors</span><span class="headingEndMark"> — </span>The anal canal is typically spared from significant radiation exposure except when radiation therapy (RT) is used to treat anal, low rectal, or gynecologic cancers. In these settings, the acute toxicity includes diarrhea caused by exposure of the rectum to irradiation. Damage to the anus itself can cause mucosal edema and friability, which can progress to desquamation or ulceration. These changes may be exacerbated by diarrhea [<a href="#rid55">55</a>]. </p><p>Acute anal toxicity is relatively common, and its incidence is increased with concurrent chemotherapy or large RT fraction size [<a href="#rid56">56-59</a>]. Conformal RT techniques may significantly decrease the incidence of skin toxicity [<a href="#rid60">60,61</a>]. Doses of 45 to 60 Gy in fractions of 1.8 to 2.0 Gy are generally considered safe, resulting in severe toxicity in 0 to 22 percent of cases. Doses above 65 Gy or fraction size above 2 Gy result in a higher incidence of toxicity [<a href="#rid56">56</a>]. There does not appear to be an increase in chronic anal toxicity when chemotherapy is combined with RT [<a href="#rid57">57,62-72</a>]. Patients with HIV who are treated with combined chemotherapy and RT may have an increased risk of acute and late anal toxicity [<a href="#rid73">73</a>].</p><p class="headingAnchor" id="H2072921577"><span class="h2">Clinical manifestations</span></p><p class="headingAnchor" id="H2308038421"><span class="h3">Acute</span><span class="headingEndMark"> — </span>Acute anal toxicity presents as a perianal skin reaction that ranges from minimal skin changes to moist desquamation and erythema. Pain typically accompanies worsening desquamation in the perianal skin region, and inflammation of the anal canal and distal rectum can also cause pain, bleeding, and tenesmus. </p><p class="headingAnchor" id="H2853987863"><span class="h3">Late</span><span class="headingEndMark"> — </span>Late toxicity can appear months to years after completion of therapy. The most common late complication is anorectal ulceration. Anal strictures (stenosis) or anorectal fistulas may also occur [<a href="#rid56">56,57,62,68</a>]. Patients usually present with anal pain and anal incontinence. </p><p class="headingAnchor" id="H1508014889"><span class="h2">Diagnosis</span><span class="headingEndMark"> — </span>The diagnosis of acute anal toxicity is suspected in patients with perianal erythema and desquamation that occurs in the setting of radiation treatment. In patients with anal ulceration or stenosis/stricture, biopsy is required to establish the diagnosis and rule out other etiologies. The evaluation of a patient with genital tract ulceration is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/7592.html" rel="external">"Approach to the patient with genital ulcers"</a>.)</p><p class="headingAnchor" id="H3914414306"><span class="h2">Differential diagnosis</span><span class="headingEndMark"> — </span>The differential diagnosis of anal ulcers includes Crohn disease and anal cancer. Other causes of perianal ulceration include infectious causes, including herpes simplex virus (genital herpes), <em>Treponema pallidum</em> (syphilis), <em>Haemophilus ducreyi</em> (chancroid), <em>Chlamydia trachomatis</em> (lymphogranuloma venereum), and <em>Klebsiella granulomatis</em>, formerly known as <em>Calymmatobacterium granulomatis</em> (donovanosis or granuloma inguinale).</p><p class="headingAnchor" id="H2963520994"><span class="h2">Management</span><span class="headingEndMark"> — </span>Management of acute toxicity is supportive and includes proper skin care, dietary modification in patients with fecal incontinence, pain medications, and corticosteroid-based suppositories. The acute RT side effects are generally self-limited and usually resolve within weeks after the end of therapy. However, treatment interruptions may be required if toxicity is severe [<a href="#rid55">55,60,63</a>].</p><p>For severe or refractory anal ulcerations, there are limited data to guide management. Case reports suggest that hyperbaric oxygen and oral <a class="drug drug_general" data-topicid="10047" href="/z/d/drug information/10047.html" rel="external">vitamin A</a> may be useful in treating anorectal ulcerations [<a href="#rid55">55,74,75</a>]. Sphincter dilation is the standard treatment for anal strictures or stenosis. Rare patients may require a colostomy if symptoms are severe.</p><p class="headingAnchor" id="H29"><span class="h1">RADIATION-INDUCED LIVER DISEASE</span></p><p class="headingAnchor" id="H599147957"><span class="h2">Pathogenesis</span><span class="headingEndMark"> — </span>The pathogenesis of radiation-induced liver disease (RILD) is not fully understood. At the tissue level, a veno-occlusive process results in retrograde congestion, leading to hemorrhage and secondary alterations in surrounding hepatocytes [<a href="#rid76">76</a>]. Acute RILD can be fatal, and hepatic toxicity can progress to fibrosis, cirrhosis, and liver failure. </p><p>Fibrin deposition in the central veins is thought to be the cause of the venoocclusive injury. The etiology of the fibrin deposition is unknown. Tumor growth factor-beta is increased during exposure to radiation, which may stimulate fibroblast migration to the site of injury, causing fibrin and collagen deposition. Foci of necrosis are found in the affected portion of the lobules [<a href="#rid77">77</a>]. (See  <a class="medical medical_review" href="/z/d/html/2837.html" rel="external">"Chemotherapy hepatotoxicity and dose modification in patients with liver disease: Conventional cytotoxic agents"</a> and  <a class="medical medical_review" href="/z/d/html/129806.html" rel="external">"Hepatic sinusoidal obstruction syndrome (veno-occlusive disease) in adults"</a> and  <a class="medical medical_review" href="/z/d/html/129806.html" rel="external">"Hepatic sinusoidal obstruction syndrome (veno-occlusive disease) in adults", section on 'Introduction'</a>.)</p><p class="headingAnchor" id="H928234863"><span class="h2">Risk factors</span><span class="headingEndMark"> — </span>The likelihood of developing RILD is directly related to the extent of liver irradiation and radiation dose delivered (the dose-volume relationship of the radiation treatment plan) [<a href="#rid77">77</a>]. Radiation hepatitis occurs in approximately 5 percent of patients when the dose of radiation to the whole liver reaches 30 to 35 Gy in 2 Gy fractions [<a href="#rid78">78,79</a>]. Significantly higher doses can be given safely if sufficient normal liver is not irradiated. Specific dose-volume relationships for the development of clinically significant liver injury following partial liver irradiation are emerging [<a href="#rid80">80,81</a>]. When considering the appropriateness of liver-directed therapy in a patient, consideration of baseline liver function is important. Patients are presently stratified based upon their Child-Pugh score. Other grading systems exist (eg, Model for End-Stage Liver Disease [MELD] score, albumin-bilirubin [ALBI] score), but they have not been extensively evaluated in patients receiving RT. Most trials investigating the use of RT in the treatment of hepatocellular carcinoma have excluded patients with severe liver disease.</p><p>Combining chemotherapy and radiation can increase liver damage, particularly when <a class="drug drug_general" data-topicid="9240" href="/z/d/drug information/9240.html" rel="external">chlorambucil</a>, <a class="drug drug_general" data-topicid="9173" href="/z/d/drug information/9173.html" rel="external">busulfan</a>, or platinum agents are used. This is a particular problem when radiation therapy is part of the conditioning regimen for bone marrow transplantation. In contrast, fluoropyrimidines do not seem to increase radiation-related hepatotoxicity [<a href="#rid79">79,82</a>]. (See  <a class="medical medical_review" href="/z/d/html/129806.html" rel="external">"Hepatic sinusoidal obstruction syndrome (veno-occlusive disease) in adults"</a>.)</p><p class="headingAnchor" id="H2434158357"><span class="h2">Clinical manifestations</span><span class="headingEndMark"> — </span>Classic RILD is a clinical syndrome consisting of anicteric hepatomegaly, ascites, and elevated liver enzymes. RILD occurs typically between two weeks and four months after completion of RT. Patients note fatigue, weight gain, increased abdominal girth, and occasionally right upper quadrant pain. Serum alkaline phosphatase levels are elevated out of proportion to other liver enzymes, and initially the total serum bilirubin level is normal. A nonclassic form of RILD can be seen in patients undergoing partial liver irradiation and consists of worsening liver function reflected in abnormal laboratory markers [<a href="#rid80">80</a>].</p><p class="headingAnchor" id="H3004221084"><span class="h2">Diagnosis</span><span class="headingEndMark"> — </span>The diagnosis of classic RILD should be suspected in patients with ascites, hepatomegaly, and elevated liver tests in the setting of recent radiation treatment. Evaluation includes exclusion of other causes of elevated liver tests. While the presence of well-demarcated areas of hypo- or hyperattenuation in a nonanatomic distribution on computed tomography scan or magnetic resonance imaging is suggestive of RILD, the diagnosis can be established on liver biopsy. (See  <a class="medical medical_review" href="/z/d/html/3576.html" rel="external">"Approach to the patient with abnormal liver biochemical and function tests"</a>.)</p><p class="headingAnchor" id="H792334697"><span class="h2">Management</span><span class="headingEndMark"> — </span>The management of patients with classic RILD is supportive and involves symptomatic management (eg, treatment of ascites). The majority of patients recover completely in three to five months, while a minority develop worsening liver fibrosis and failure, rarely developing fulminant hepatic failure.</p><p class="headingAnchor" id="H2230265082"><span class="h1">PREVENTION</span><span class="headingEndMark"> — </span>Multiple techniques are used to decrease the volumes of nontarget gastrointestinal tissues treated, including the use of multiple treatment fields to avoid "hot spots," treating in the prone position, use of a "belly board" or false table-top, as well as treating with a full bladder to displace bowel out of the radiation therapy (RT) field [<a href="#rid83">83</a>].</p><p>Improved imaging and computer capabilities have made three-dimensional (3D) treatment planning widely available, in contrast to the two-dimensional approaches used in the past. Intensity-modulated RT, an advanced form of 3D planning, is widely used and utilization and may permit further dose escalation while decreasing toxicity [<a href="#rid84">84,85</a>] (see  <a class="medical medical_review" href="/z/d/html/89528.html" rel="external">"Radiation therapy techniques in cancer treatment", section on 'Intensity-modulated radiation therapy'</a>). Similarly, the use of proton therapy, a form of particle therapy, may further enhance normal tissue sparing through its' inherent dose-distribution properties.</p><p>Several chemopreventive agents have been evaluated for preventing radiation-induced toxicity in the gastrointestinal tract. However, none have an established role, other than <a class="drug drug_general" data-topicid="8533" href="/z/d/drug information/8533.html" rel="external">amifostine</a>, for prevention of xerostomia in patients receiving RT only for head and neck cancer. (See  <a class="medical medical_review" href="/z/d/html/3408.html" rel="external">"Management and prevention of complications during initial treatment of head and neck cancer", section on 'Amifostine'</a>.)</p><p class="headingAnchor" id="H312691107"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/116292.html" rel="external">"Society guideline links: Radiation-induced gastrointestinal toxicity"</a>.)</p><p class="headingAnchor" id="H30"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span>Gastrointestinal toxicity can occur following irradiation of thoracic, abdominal, or pelvic malignancies if gastrointestinal structures are located within the radiation therapy (RT) field. These toxicities can limit the maximum tolerated dose of RT and chemotherapy and thus may limit the efficacy of treatment. (See <a class="local">'Introduction'</a> above and <a class="local">'Timing of toxicity'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The incidence and severity of RT side effects depend upon the site, volume of tissue exposed, and treatment schedule, including total dose, dose per fraction, and type of radiation. Other risk factors for radiation induced GI toxicity include the use of concomitant chemotherapy. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Symptoms of acute radiation esophagitis include dysphagia, odynophagia, and substernal discomfort. Patients with late toxicity often present with dysphagia secondary to stricture or altered motility caused by fibrosis/muscular damage or nerve injury or odynophagia due to chronic ulceration. (See <a class="local">'Esophagitis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Acute radiation gastritis can cause nausea and vomiting within 24 hours after the start of treatment. Symptoms generally resolve within one to two weeks following completion of RT. Manifestations of late radiation gastritis include abdominal pain due to nonulcer dyspepsia, gastric ulcers, and antral stenosis. (See <a class="local">'Gastritis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Symptoms of acute radiation enteritis include diarrhea, abdominal pain, nausea and vomiting, anorexia, and malaise. Radiation-induced diarrhea often appears during the third week of treatment and typically disappears two to six weeks after the completion of RT. Late effects include malabsorption and diarrhea. Patients may have bloating, excessive gas, and borborygmi due to small intestinal bacterial overgrowth. Other symptoms include bleeding or abdominal pain due to ulceration, and fever secondary to abscess formation. Patients with severe disease may develop intermittent, partial, or complete small bowel obstruction due to strictures. (See <a class="local">'Enteritis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Acute anal toxicity presents as a perianal skin reaction that ranges from minimal skin changes to moist desquamation and erythema. Late complications of RT include anorectal ulceration, anal strictures or stenosis, and anorectal fistulas. Patients with late anal radiation toxicity usually present with anal pain and anal incontinence. (See <a class="local">'Anal toxicity'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with radiation-induced liver disease present with fatigue, weight gain, increased abdominal girth, and occasionally right upper quadrant pain. On physical examination, patients have hepatomegaly and ascites. Laboratory findings include elevated alkaline phosphatase, but transaminases and bilirubin remain may normal. However, patients with underlying liver disease present with jaundice and markedly elevated serum transaminase (more than five times the upper limit of normal). (See <a class="local">'Radiation-induced liver disease'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Multiple techniques are used to decrease the volumes of nontarget gastrointestinal tissues treated, including the use of multiple treatment fields to avoid "hot spots," treating in the prone position, use of a "belly board" or false table-top, as well as treating with a full bladder to displace bowel out of the RT field and use of intensity-modulated radiation therapy. (See <a class="local">'Prevention'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Emami B, Lyman J, Brown A, et al. Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys 1991; 21:109.</a></li><li><a class="nounderline abstract_t">SEAMAN WB, ACKERMAN LV. The effect of radiation on the esophagus; a clinical and histologic study of the effects produced by the betatron. Radiology 1957; 68:534.</a></li><li><a class="nounderline abstract_t">Morichau-Beauchant M, Touchard G, Battandier D, et al. [Chronic radiation-induced esophagitis after treatment of oropharyngolaryngeal cancer: a little-known anatomo-clinical entity]. Gastroenterol Clin Biol 1983; 7:843.</a></li><li><a class="nounderline abstract_t">Kramer S, Gelberr R, Snow J. Preopertive versus postoperative radiation therapy in advanced squamous cell carcinoma of the head and neck: Final report on RTOG 73-03. Am J Clin Oncol (CCT) 1983; 6:150.</a></li><li><a class="nounderline abstract_t">Maguire PD, Sibley GS, Zhou SM, et al. Clinical and dosimetric predictors of radiation-induced esophageal toxicity. Int J Radiat Oncol Biol Phys 1999; 45:97.</a></li><li><a class="nounderline abstract_t">Bradley JD, Paulus R, Komaki R, et al. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study. Lancet Oncol 2015; 16:187.</a></li><li><a class="nounderline abstract_t">Cooper JS, Guo MD, Herskovic A, et al. Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01). Radiation Therapy Oncology Group. JAMA 1999; 281:1623.</a></li><li><a class="nounderline abstract_t">Freilich J, Hoffe SE, Almhanna K, et al. Comparative outcomes for three-dimensional conformal versus intensity-modulated radiation therapy for esophageal cancer. Dis Esophagus 2015; 28:352.</a></li><li><a class="nounderline abstract_t">Singh AK, Lockett MA, Bradley JD. Predictors of radiation-induced esophageal toxicity in patients with non-small-cell lung cancer treated with three-dimensional conformal radiotherapy. Int J Radiat Oncol Biol Phys 2003; 55:337.</a></li><li><a class="nounderline abstract_t">Byhardt RW, Scott C, Sause WT, et al. Response, toxicity, failure patterns, and survival in five Radiation Therapy Oncology Group (RTOG) trials of sequential and/or concurrent chemotherapy and radiotherapy for locally advanced non-small-cell carcinoma of the lung. Int J Radiat Oncol Biol Phys 1998; 42:469.</a></li><li><a class="nounderline abstract_t">Chowhan NM. Injurious effects of radiation on the esophagus. Am J Gastroenterol 1990; 85:115.</a></li><li><a class="nounderline abstract_t">Berthrong M, Fajardo LF. Radiation injury in surgical pathology. Part II. Alimentary tract. Am J Surg Pathol 1981; 5:153.</a></li><li><a class="nounderline abstract_t">O'Rourke IC, Tiver K, Bull C, et al. Swallowing performance after radiation therapy for carcinoma of the esophagus. Cancer 1988; 61:2022.</a></li><li><a class="nounderline abstract_t">Coia LR, Myerson RJ, Tepper JE. Late effects of radiation therapy on the gastrointestinal tract. Int J Radiat Oncol Biol Phys 1995; 31:1213.</a></li><li><a class="nounderline abstract_t">Phillips TL, Ross G. Time-dose relationships in the mouse esophagus. Radiology 1974; 113:435.</a></li><li><a class="nounderline abstract_t">Sasso FS, Sasso G, Marsiglia HR, et al. Pharmacological and dietary prophylaxis and treatment of acute actinic esophagitis during mediastinal radiotherapy. Dig Dis Sci 2001; 46:746.</a></li><li><a class="nounderline abstract_t">GOLDGRABER MB, RUBIN CE, PALMER WL, et al. The early gastric response to irradiation; a serial biopsy study. Gastroenterology 1954; 27:1.</a></li><li><a class="nounderline abstract_t">Cosset JM, Henry-Amar M, Burgers JM, et al. Late radiation injuries of the gastrointestinal tract in the H2 and H5 EORTC Hodgkin's disease trials: emphasis on the role of exploratory laparotomy and fractionation. Radiother Oncol 1988; 13:61.</a></li><li><a class="nounderline abstract_t">Pearson JG. The present status and future potential of radiotherapy in the management of esophageal cancer. Cancer 1977; 39:882.</a></li><li><a class="nounderline abstract_t">Gunderson LL, Hoskins RB, Cohen AC, et al. Combined modality treatment of gastric cancer. Int J Radiat Oncol Biol Phys 1983; 9:965.</a></li><li><a class="nounderline abstract_t">Hamilton CR, Horwich A, Bliss JM, Peckham MJ. Gastrointestinal morbidity of adjuvant radiotherapy in stage I malignant teratoma of the testis. Radiother Oncol 1987; 10:85.</a></li><li><a class="nounderline abstract_t">Henriksson R, Bergström P, Franzén L, et al. Aspects on reducing gastrointestinal adverse effects associated with radiotherapy. Acta Oncol 1999; 38:159.</a></li><li><a class="nounderline abstract_t">Sell A, Jensen TS. Acute gastric ulcers induced by radiation. Acta Radiol Ther Phys Biol 1966; 4:289.</a></li><li><a class="nounderline abstract_t">Hasleton PS, Carr N, Schofield PF. Vascular changes in radiation bowel disease. Histopathology 1985; 9:517.</a></li><li><a class="nounderline abstract_t">Schofield PF, Carr ND, Holden D. Pathogenesis and treatment of radiation bowel disease: discussion paper. J R Soc Med 1986; 79:30.</a></li><li><a class="nounderline abstract_t">Greenberger N, Isselbacher K. Malabsorption following radiation injury to the gastrointestinal tract. Am J Med 1964; 36:450.</a></li><li><a class="nounderline abstract_t">Galland RB, Spencer J. Spontaneous postoperative perforation of previously asymptomatic irradiated bowel. Br J Surg 1985; 72:285.</a></li><li><a class="nounderline abstract_t">Yeoh E, Horowitz M, Russo A, et al. Effect of pelvic irradiation on gastrointestinal function: a prospective longitudinal study. Am J Med 1993; 95:397.</a></li><li><a class="nounderline abstract_t">Husebye E, Hauer-Jensen M, Kjørstad K, Skar V. Severe late radiation enteropathy is characterized by impaired motility of proximal small intestine. Dig Dis Sci 1994; 39:2341.</a></li><li><a class="nounderline abstract_t">Wedlake L, Thomas K, McGough C, Andreyev HJ. Small bowel bacterial overgrowth and lactose intolerance during radical pelvic radiotherapy: An observational study. Eur J Cancer 2008; 44:2212.</a></li><li><a class="nounderline abstract_t">Buchler DA, Kline JC, Peckham BM, et al. Radiation reactions in cervical cancer therapy. Am J Obstet Gynecol 1971; 111:745.</a></li><li><a class="nounderline abstract_t">Kao MS. Intestinal complications of radiotherapy in gynecologic malignancy--clinical presentation and management. Int J Gynaecol Obstet 1995; 49 Suppl:S69.</a></li><li><a class="nounderline abstract_t">Baglan KL, Frazier RC, Yan D, et al. The dose-volume relationship of acute small bowel toxicity from concurrent 5-FU-based chemotherapy and radiation therapy for rectal cancer. Int J Radiat Oncol Biol Phys 2002; 52:176.</a></li><li><a class="nounderline abstract_t">Tho LM, Glegg M, Paterson J, et al. Acute small bowel toxicity and preoperative chemoradiotherapy for rectal cancer: investigating dose-volume relationships and role for inverse planning. Int J Radiat Oncol Biol Phys 2006; 66:505.</a></li><li><a class="nounderline abstract_t">Gunnlaugsson A, Kjellén E, Nilsson P, et al. Dose-volume relationships between enteritis and irradiated bowel volumes during 5-fluorouracil and oxaliplatin based chemoradiotherapy in locally advanced rectal cancer. Acta Oncol 2007; 46:937.</a></li><li><a class="nounderline abstract_t">Czito BG, Willett CG, Bendell JC, et al. Increased toxicity with gefitinib, capecitabine, and radiation therapy in pancreatic and rectal cancer: phase I trial results. J Clin Oncol 2006; 24:656.</a></li><li><a class="nounderline abstract_t">Cancer and Leukemia Group B 89901, Ryan DP, Niedzwiecki D, et al. Phase I/II study of preoperative oxaliplatin, fluorouracil, and external-beam radiation therapy in patients with locally advanced rectal cancer: Cancer and Leukemia Group B 89901. J Clin Oncol 2006; 24:2557.</a></li><li><a class="nounderline abstract_t">Mohiuddin M, Winter K, Mitchell E, et al. Randomized phase II study of neoadjuvant combined-modality chemoradiation for distal rectal cancer: Radiation Therapy Oncology Group Trial 0012. J Clin Oncol 2006; 24:650.</a></li><li><a class="nounderline abstract_t">Letschert JG, Lebesque JV, Aleman BM, et al. The volume effect in radiation-related late small bowel complications: results of a clinical study of the EORTC Radiotherapy Cooperative Group in patients treated for rectal carcinoma. Radiother Oncol 1994; 32:116.</a></li><li><a class="nounderline abstract_t">Louidice T, Baxter D, Bailint J. Effects of abdominal surgery on the development of radiation enteropathy. Gastroenterol 1977; 73:1093.</a></li><li><a class="nounderline abstract_t">Green N. The avoidance of small intestine injury in gynecologic cancer. Int J Radiat Oncol Biol Phys 1983; 9:1385.</a></li><li><a class="nounderline abstract_t">Eifel PJ, Levenback C, Wharton JT, Oswald MJ. Time course and incidence of late complications in patients treated with radiation therapy for FIGO stage IB carcinoma of the uterine cervix. Int J Radiat Oncol Biol Phys 1995; 32:1289.</a></li><li><a class="nounderline abstract_t">Stockbrine M, Hancock J, Fletcher G. Complications in 831 patients with squamous cell carcinoma of the intact uterine cervix treated with 3000 rads or more whole pelvis radiation. Am J Roentgenol 1970; 108:283.</a></li><li><a class="nounderline abstract_t">Loiudice TA, Lang JA. Treatment of radiation enteritis: a comparison study. Am J Gastroenterol 1983; 78:481.</a></li><li><a class="nounderline abstract_t">DeCosse JJ, Rhodes RS, Wentz WB, et al. The natural history and management of radiation induced injury of the gastrointestinal tract. Ann Surg 1969; 170:369.</a></li><li><a class="nounderline abstract_t">Chon BH, Loeffler JS. The effect of nonmalignant systemic disease on tolerance to radiation therapy. Oncologist 2002; 7:136.</a></li><li><a class="nounderline abstract_t">Song DY, Lawrie WT, Abrams RA, et al. Acute and late radiotherapy toxicity in patients with inflammatory bowel disease. Int J Radiat Oncol Biol Phys 2001; 51:455.</a></li><li><a class="nounderline abstract_t">Willett CG, Ooi CJ, Zietman AL, et al. Acute and late toxicity of patients with inflammatory bowel disease undergoing irradiation for abdominal and pelvic neoplasms. Int J Radiat Oncol Biol Phys 2000; 46:995.</a></li><li><a class="nounderline abstract_t">Lin A, Abu-Isa E, Griffith KA, Ben-Josef E. Toxicity of radiotherapy in patients with collagen vascular disease. Cancer 2008; 113:648.</a></li><li><a class="nounderline abstract_t">Green S, Stock RG, Greenstein AJ. Rectal cancer and inflammatory bowel disease: natural history and implications for radiation therapy. Int J Radiat Oncol Biol Phys 1999; 44:835.</a></li><li><a class="nounderline abstract_t">Classen J, Belka C, Paulsen F, et al. Radiation-induced gastrointestinal toxicity. Pathophysiology, approaches to treatment and prophylaxis. Strahlenther Onkol 1998; 174 Suppl 3:82.</a></li><li><a class="nounderline abstract_t">Hauer-Jensen M. Late radiation injury of the small intestine. Clinical, pathophysiologic and radiobiologic aspects. A review. Acta Oncol 1990; 29:401.</a></li><li><a class="nounderline abstract_t">Kwitko AO, Pieterse AS, Hecker R, et al. Chronic radiation injury to the intestine: a clinico-pathological study. Aust N Z J Med 1982; 12:272.</a></li><li><a class="nounderline abstract_t">Sher ME, Bauer J. Radiation-induced enteropathy. Am J Gastroenterol 1990; 85:121.</a></li><li><a class="nounderline abstract_t">Levitsky J, Hong JJ, Jani AB, Ehrenpreis ED. Oral vitamin a therapy for a patient with a severely symptomatic postradiation anal ulceration: report of a case. Dis Colon Rectum 2003; 46:679.</a></li><li><a class="nounderline abstract_t">Mitchell SE, Mendenhall WM, Zlotecki RA, Carroll RR. Squamous cell carcinoma of the anal canal. Int J Radiat Oncol Biol Phys 2001; 49:1007.</a></li><li><a class="nounderline abstract_t">Flam MS, John MJ, Mowry PA, et al. Definitive combined modality therapy of carcinoma of the anus. A report of 30 cases including results of salvage therapy in patients with residual disease. Dis Colon Rectum 1987; 30:495.</a></li><li><a class="nounderline abstract_t">Cummings B, Keane T, Thomas G, et al. Results and toxicity of the treatment of anal canal carcinoma by radiation therapy or radiation therapy and chemotherapy. Cancer 1984; 54:2062.</a></li><li><a class="nounderline abstract_t">Myerson RJ, Kong F, Birnbaum EH, et al. Radiation therapy for epidermoid carcinoma of the anal canal, clinical and treatment factors associated with outcome. Radiother Oncol 2001; 61:15.</a></li><li><a class="nounderline abstract_t">Salama JK, Mell LK, Schomas DA, et al. Concurrent chemotherapy and intensity-modulated radiation therapy for anal canal cancer patients: a multicenter experience. J Clin Oncol 2007; 25:4581.</a></li><li><a class="nounderline abstract_t">Vuong T, Devic S, Belliveau P, et al. Contribution of conformal therapy in the treatment of anal canal carcinoma with combined chemotherapy and radiotherapy: results of a phase II study. Int J Radiat Oncol Biol Phys 2003; 56:823.</a></li><li><a class="nounderline abstract_t">Gabriele AM, Rovea P, Sola B, et al. Radiation therapy and chemotherapy in the conservative treatment of carcinoma of the anal canal: survival and late morbidity in a series of 25 patients. Anticancer Res 1997; 17:653.</a></li><li><a class="nounderline abstract_t">Flam M, John M, Pajak TF, et al. Role of mitomycin in combination with fluorouracil and radiotherapy, and of salvage chemoradiation in the definitive nonsurgical treatment of epidermoid carcinoma of the anal canal: results of a phase III randomized intergroup study. J Clin Oncol 1996; 14:2527.</a></li><li><a class="nounderline abstract_t">Bartelink H, Roelofsen F, Eschwege F, et al. Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: results of a phase III randomized trial of the European Organization for Research and Treatment of Cancer Radiotherapy and Gastrointestinal Cooperative Groups. J Clin Oncol 1997; 15:2040.</a></li><li><a class="nounderline abstract_t">Epidermoid anal cancer: results from the UKCCCR randomised trial of radiotherapy alone versus radiotherapy, 5-fluorouracil, and mitomycin. UKCCCR Anal Cancer Trial Working Party. UK Co-ordinating Committee on Cancer Research. Lancet 1996; 348:1049.</a></li><li><a class="nounderline abstract_t">Rich TA, Ajani JA, Morrison WH, et al. Chemoradiation therapy for anal cancer: radiation plus continuous infusion of 5-fluorouracil with or without cisplatin. Radiother Oncol 1993; 27:209.</a></li><li><a class="nounderline abstract_t">John M, Flam M, Palma N. Ten-year results of chemoradiation for anal cancer: focus on late morbidity. Int J Radiat Oncol Biol Phys 1996; 34:65.</a></li><li><a class="nounderline abstract_t">Peiffert D, Bey P, Pernot M, et al. Conservative treatment by irradiation of epidermoid cancers of the anal canal: prognostic factors of tumoral control and complications. Int J Radiat Oncol Biol Phys 1997; 37:313.</a></li><li><a class="nounderline abstract_t">Cantril ST, Green JP, Schall GL, Schaupp WC. Primary radiation therapy in the treatment of anal carcinoma. Int J Radiat Oncol Biol Phys 1983; 9:1271.</a></li><li><a class="nounderline abstract_t">Eschwege F, Lasser P, Chavy A, et al. Squamous cell carcinoma of the anal canal: treatment by external beam irradiation. Radiother Oncol 1985; 3:145.</a></li><li><a class="nounderline abstract_t">Tanum G, Tveit K, Karlsen KO, Hauer-Jensen M. Chemotherapy and radiation therapy for anal carcinoma. Survival and late morbidity. Cancer 1991; 67:2462.</a></li><li><a class="nounderline abstract_t">John M, Pajak T, Flam M, et al. Dose escalation in chemoradiation for anal cancer: preliminary results of RTOG 92-08. Cancer J Sci Am 1996; 2:205.</a></li><li><a class="nounderline abstract_t">Kim JH, Sarani B, Orkin BA, et al. HIV-positive patients with anal carcinoma have poorer treatment tolerance and outcome than HIV-negative patients. Dis Colon Rectum 2001; 44:1496.</a></li><li><a class="nounderline abstract_t">Bem J, Bem S, Singh A. Use of hyperbaric oxygen chamber in the management of radiation-related complications of the anorectal region: report of two cases and review of the literature. Dis Colon Rectum 2000; 43:1435.</a></li><li><a class="nounderline abstract_t">Bennett MH, Feldmeier J, Hampson N, et al. Hyperbaric oxygen therapy for late radiation tissue injury. Cochrane Database Syst Rev 2012; :CD005005.</a></li><li><a class="nounderline abstract_t">Dawson LA, Ten Haken RK. Partial volume tolerance of the liver to radiation. Semin Radiat Oncol 2005; 15:279.</a></li><li><a class="nounderline abstract_t">OGATA K, HIZAWA K, YOSHIDA M, et al. HEPATIC INJURY FOLLOWING IRRADIATION--A MORPHOLOGIC STUDY--. Tokushima J Exp Med 1963; 10:240.</a></li><li class="breakAll">Constine L, Williams J, Morris M, et al. Late effects of cancer treatment on normal tissues. In: Principles and Practice of Radiation Oncology, Perez C, Brady L, Halperin E, Schmidt-Urrlich R (Eds), Lippincott Wiliams &amp; Wilkins, Philadelphia 2004. p.357.</li><li><a class="nounderline abstract_t">Lawrence TS, Robertson JM, Anscher MS, et al. Hepatic toxicity resulting from cancer treatment. Int J Radiat Oncol Biol Phys 1995; 31:1237.</a></li><li><a class="nounderline abstract_t">Pan CC, Kavanagh BD, Dawson LA, et al. Radiation-associated liver injury. Int J Radiat Oncol Biol Phys 2010; 76:S94.</a></li><li><a class="nounderline abstract_t">Pursley J, El Naqa I, Sanford NN, et al. Dosimetric Analysis and Normal-Tissue Complication Probability Modeling of Child-Pugh Score and Albumin-Bilirubin Grade Increase After Hepatic Irradiation. Int J Radiat Oncol Biol Phys 2020; 107:986.</a></li><li><a class="nounderline abstract_t">Lawrence TS, Ten Haken RK, Kessler ML, et al. The use of 3-D dose volume analysis to predict radiation hepatitis. Int J Radiat Oncol Biol Phys 1992; 23:781.</a></li><li><a class="nounderline abstract_t">Gallagher MJ, Brereton HD, Rostock RA, et al. A prospective study of treatment techniques to minimize the volume of pelvic small bowel with reduction of acute and late effects associated with pelvic irradiation. Int J Radiat Oncol Biol Phys 1986; 12:1565.</a></li><li><a class="nounderline abstract_t">Klopp AH, Yeung AR, Deshmukh S, et al. Patient-Reported Toxicity During Pelvic Intensity-Modulated Radiation Therapy: NRG Oncology-RTOG 1203. J Clin Oncol 2018; 36:2538.</a></li><li><a class="nounderline abstract_t">Chopra S, Gupta S, Kannan S, et al. Late Toxicity After Adjuvant Conventional Radiation Versus Image-Guided Intensity-Modulated Radiotherapy for Cervical Cancer (PARCER): A Randomized Controlled Trial. J Clin Oncol 2021; 39:3682.</a></li></ol></div><div id="topicVersionRevision">Topic 7054 Version 21.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2032882" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Tolerance of normal tissue to therapeutic irradiation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13432180" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : The effect of radiation on the esophagus; a clinical and histologic study of the effects produced by the betatron.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6653970" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : [Chronic radiation-induced esophagitis after treatment of oropharyngolaryngeal cancer: a little-known anatomo-clinical entity].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Preopertive versus postoperative radiation therapy in advanced squamous cell carcinoma of the head and neck: Final report on RTOG 73-03</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10477012" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Clinical and dosimetric predictors of radiation-induced esophageal toxicity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25601342" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10235156" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01). Radiation Therapy Oncology Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24635657" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Comparative outcomes for three-dimensional conformal versus intensity-modulated radiation therapy for esophageal cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12527046" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Predictors of radiation-induced esophageal toxicity in patients with non-small-cell lung cancer treated with three-dimensional conformal radiotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9806503" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Response, toxicity, failure patterns, and survival in five Radiation Therapy Oncology Group (RTOG) trials of sequential and/or concurrent chemotherapy and radiotherapy for locally advanced non-small-cell carcinoma of the lung.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2405641" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Injurious effects of radiation on the esophagus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7013506" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Radiation injury in surgical pathology. Part II. Alimentary tract.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2452006" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Swallowing performance after radiation therapy for carcinoma of the esophagus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7713784" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Late effects of radiation therapy on the gastrointestinal tract.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4417427" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Time-dose relationships in the mouse esophagus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11330407" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Pharmacological and dietary prophylaxis and treatment of acute actinic esophagitis during mediastinal radiotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13173804" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : The early gastric response to irradiation; a serial biopsy study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3141982" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Late radiation injuries of the gastrointestinal tract in the H2 and H5 EORTC Hodgkin's disease trials: emphasis on the role of exploratory laparotomy and fractionation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/402201" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : The present status and future potential of radiotherapy in the management of esophageal cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6688072" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Combined modality treatment of gastric cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3423305" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Gastrointestinal morbidity of adjuvant radiotherapy in stage I malignant teratoma of the testis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10227436" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Aspects on reducing gastrointestinal adverse effects associated with radiotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5920641" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Acute gastric ulcers induced by radiation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4007790" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Vascular changes in radiation bowel disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3944818" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Pathogenesis and treatment of radiation bowel disease: discussion paper.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Malabsorption following radiation injury to the gastrointestinal tract</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3986478" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Spontaneous postoperative perforation of previously asymptomatic irradiated bowel.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8213872" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Effect of pelvic irradiation on gastrointestinal function: a prospective longitudinal study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7956601" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Severe late radiation enteropathy is characterized by impaired motility of proximal small intestine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18760593" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Small bowel bacterial overgrowth and lactose intolerance during radical pelvic radiotherapy: An observational study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5001415" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Radiation reactions in cervical cancer therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7589743" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Intestinal complications of radiotherapy in gynecologic malignancy--clinical presentation and management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11777636" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : The dose-volume relationship of acute small bowel toxicity from concurrent 5-FU-based chemotherapy and radiation therapy for rectal cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16879928" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Acute small bowel toxicity and preoperative chemoradiotherapy for rectal cancer: investigating dose-volume relationships and role for inverse planning.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17851844" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Dose-volume relationships between enteritis and irradiated bowel volumes during 5-fluorouracil and oxaliplatin based chemoradiotherapy in locally advanced rectal cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16446337" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Increased toxicity with gefitinib, capecitabine, and radiation therapy in pancreatic and rectal cancer: phase I trial results.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16636336" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Phase I/II study of preoperative oxaliplatin, fluorouracil, and external-beam radiation therapy in patients with locally advanced rectal cancer: Cancer and Leukemia Group B 89901.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16446336" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Randomized phase II study of neoadjuvant combined-modality chemoradiation for distal rectal cancer: Radiation Therapy Oncology Group Trial 0012.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7972904" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : The volume effect in radiation-related late small bowel complications: results of a clinical study of the EORTC Radiotherapy Cooperative Group in patients treated for rectal carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Effects of abdominal surgery on the development of radiation enteropathy</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6193089" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : The avoidance of small intestine injury in gynecologic cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7635768" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Time course and incidence of late complications in patients treated with radiation therapy for FIGO stage IB carcinoma of the uterine cervix.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Complications in 831 patients with squamous cell carcinoma of the intact uterine cervix treated with 3000 rads or more whole pelvis radiation</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6410908" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Treatment of radiation enteritis: a comparison study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4979653" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : The natural history and management of radiation induced injury of the gastrointestinal tract.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11961197" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : The effect of nonmalignant systemic disease on tolerance to radiation therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11567821" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Acute and late radiotherapy toxicity in patients with inflammatory bowel disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10705022" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Acute and late toxicity of patients with inflammatory bowel disease undergoing irradiation for abdominal and pelvic neoplasms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18506734" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Toxicity of radiotherapy in patients with collagen vascular disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10386640" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Rectal cancer and inflammatory bowel disease: natural history and implications for radiation therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9830465" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Radiation-induced gastrointestinal toxicity. Pathophysiology, approaches to treatment and prophylaxis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2202341" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Late radiation injury of the small intestine. Clinical, pathophysiologic and radiobiologic aspects. A review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6956295" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Chronic radiation injury to the intestine: a clinico-pathological study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2301333" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Radiation-induced enteropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12792447" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Oral vitamin a therapy for a patient with a severely symptomatic postradiation anal ulceration: report of a case.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11240241" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Squamous cell carcinoma of the anal canal.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3109860" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Definitive combined modality therapy of carcinoma of the anus. A report of 30 cases including results of salvage therapy in patients with residual disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6435851" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Results and toxicity of the treatment of anal canal carcinoma by radiation therapy or radiation therapy and chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11578724" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Radiation therapy for epidermoid carcinoma of the anal canal, clinical and treatment factors associated with outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17925552" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Concurrent chemotherapy and intensity-modulated radiation therapy for anal canal cancer patients: a multicenter experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12788191" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Contribution of conformal therapy in the treatment of anal canal carcinoma with combined chemotherapy and radiotherapy: results of a phase II study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9066596" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Radiation therapy and chemotherapy in the conservative treatment of carcinoma of the anal canal: survival and late morbidity in a series of 25 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8823332" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Role of mitomycin in combination with fluorouracil and radiotherapy, and of salvage chemoradiation in the definitive nonsurgical treatment of epidermoid carcinoma of the anal canal: results of a phase III randomized intergroup study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9164216" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: results of a phase III randomized trial of the European Organization for Research and Treatment of Cancer Radiotherapy and Gastrointestinal Cooperative Groups.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8874455" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Epidermoid anal cancer: results from the UKCCCR randomised trial of radiotherapy alone versus radiotherapy, 5-fluorouracil, and mitomycin. UKCCCR Anal Cancer Trial Working Party. UK Co-ordinating Committee on Cancer Research.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8210457" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Chemoradiation therapy for anal cancer: radiation plus continuous infusion of 5-fluorouracil with or without cisplatin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12118566" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Ten-year results of chemoradiation for anal cancer: focus on late morbidity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9069302" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Conservative treatment by irradiation of epidermoid cancers of the anal canal: prognostic factors of tumoral control and complications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6885539" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Primary radiation therapy in the treatment of anal carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3920734" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Squamous cell carcinoma of the anal canal: treatment by external beam irradiation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2015547" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Chemotherapy and radiation therapy for anal carcinoma. Survival and late morbidity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9166533" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Dose escalation in chemoradiation for anal cancer: preliminary results of RTOG 92-08.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11598480" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : HIV-positive patients with anal carcinoma have poorer treatment tolerance and outcome than HIV-negative patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11052522" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Use of hyperbaric oxygen chamber in the management of radiation-related complications of the anorectal region: report of two cases and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22592699" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Hyperbaric oxygen therapy for late radiation tissue injury.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16183482" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Partial volume tolerance of the liver to radiation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14049847" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : HEPATIC INJURY FOLLOWING IRRADIATION--A MORPHOLOGIC STUDY--.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14049847" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : HEPATIC INJURY FOLLOWING IRRADIATION--A MORPHOLOGIC STUDY--.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7713785" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Hepatic toxicity resulting from cancer treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20171524" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Radiation-associated liver injury.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32353390" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Dosimetric Analysis and Normal-Tissue Complication Probability Modeling of Child-Pugh Score and Albumin-Bilirubin Grade Increase After Hepatic Irradiation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1618671" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : The use of 3-D dose volume analysis to predict radiation hepatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3759581" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : A prospective study of treatment techniques to minimize the volume of pelvic small bowel with reduction of acute and late effects associated with pelvic irradiation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29989857" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Patient-Reported Toxicity During Pelvic Intensity-Modulated Radiation Therapy: NRG Oncology-RTOG 1203.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34506246" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Late Toxicity After Adjuvant Conventional Radiation Versus Image-Guided Intensity-Modulated Radiotherapy for Cervical Cancer (PARCER): A Randomized Controlled Trial.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
